Doxepin

Sinequan, Silenor, Prudoxin, Zonalon

Antidepressant • Tricyclic antidepressant (TCA)

Premium

NTIQT RiskSerotoninergicCNS Depressant

Half-life

8-24 hours

Protein Binding

80%

Metabolized By

CYP2C19, CYP2D6

External

Drugs.com

Boxed warning

Suicidality in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Inhibits norepinephrine and serotonin reuptake; potent H1 antihistamine

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Acute Oral Mucositis Pain
·Swallowing-induced Pain
·Itch
·Bipolar Disorder
·Functional Gastrointestinal Disorders

Interactions

No curated interaction pairs are recorded for Doxepin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Drowsiness
Dry mouth
Constipation
Weight gain
Blurred vision

Food, alcohol & herbal

Food

High-fat meal delays and increases absorption (Silenor)

Alcohol · major

Severe CNS depression

Pharmacokinetics

Half-life: 8-24 hours
Protein binding: 80%
Metabolised by: CYP2C19, CYP2D6

Pregnancy & lactation

Not recorded for Doxepin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Doxepin

Sinequan, Silenor, Prudoxin, Zonalon

Antidepressant • Tricyclic antidepressant (TCA)

Premium

NTIQT RiskSerotoninergicCNS Depressant

Half-life

8-24 hours

Protein Binding

80%

Metabolized By

CYP2C19, CYP2D6

External

Drugs.com

Boxed warning

Suicidality in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Inhibits norepinephrine and serotonin reuptake; potent H1 antihistamine

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Acute Oral Mucositis Pain
·Swallowing-induced Pain
·Itch
·Bipolar Disorder
·Functional Gastrointestinal Disorders

Interactions

No curated interaction pairs are recorded for Doxepin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Drowsiness
Dry mouth
Constipation
Weight gain
Blurred vision

Food, alcohol & herbal

Food

High-fat meal delays and increases absorption (Silenor)

Alcohol · major

Severe CNS depression

Pharmacokinetics

Half-life: 8-24 hours
Protein binding: 80%
Metabolised by: CYP2C19, CYP2D6

Pregnancy & lactation

Not recorded for Doxepin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Doxepin Drug Profile | PharmaGraphX